Regeneron has a winner in Dupixent and big sales hopes. So why are so few patients taking it?
One of the true biotech success stories, New York’s Regeneron has set its ambitions sky high with two blockbusters in their back pocket and some …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
